ZYKADIA Drug Patent Profile

When do Zykadia patents expire, and when can generic versions of Zykadia launch?

Zykadia is a drug marketed by Novartis and is included in two NDAs. There are eight patents protecting this drug.

This drug has three hundred and twenty-two patent family members in fifty-six countries.

The generic ingredient in ZYKADIA is ceritinib. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the ceritinib profile page.

DrugPatentWatch^® Generic Entry Outlook for Zykadia

Zykadia was eligible for patent challenges on April 29, 2018.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be June 29, 2030. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for ZYKADIA

International Patents:	322
US Patents:	8
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	78
Clinical Trials:	11
Patent Applications:	3,404
Drug Prices:	Drug price information for ZYKADIA
What excipients (inactive ingredients) are in ZYKADIA?	ZYKADIA excipients list
DailyMed Link:	ZYKADIA at DailyMed

See drug prices for ZYKADIA

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for ZYKADIA

NDA:

205755

Dosage:

CAPSULE;ORAL

NDA:

211225

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for ZYKADIA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Plateforme labellisée Inca – Institut Bergonié, Bordeaux	Phase 3
Plateforme labellisée Inca - Hôpital Européen Georges Pompidou, Paris	Phase 3
Commissariat A L'energie Atomique	Phase 3

See all ZYKADIA clinical trials

Pharmacology for ZYKADIA

Drug Class	Kinase Inhibitor
Mechanism of Action	Cytochrome P450 2C9 Inhibitors Cytochrome P450 3A Inhibitors Tyrosine Kinase Inhibitors

US Patents and Regulatory Information for ZYKADIA

ZYKADIA is protected by eight US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	ZYKADIA	ceritinib	CAPSULE;ORAL	205755-001	Apr 29, 2014		DISCN	Yes	No
Novartis	ZYKADIA	ceritinib	CAPSULE;ORAL	205755-001	Apr 29, 2014		DISCN	Yes	No			Y	Y
Novartis	ZYKADIA	ceritinib	CAPSULE;ORAL	205755-001	Apr 29, 2014		DISCN	Yes	No			Y	Y
Novartis	ZYKADIA	ceritinib	TABLET;ORAL	211225-001	Mar 18, 2019		RX	Yes	Yes			Y	Y
Novartis	ZYKADIA	ceritinib	TABLET;ORAL	211225-001	Mar 18, 2019		RX	Yes	Yes
Novartis	ZYKADIA	ceritinib	TABLET;ORAL	211225-001	Mar 18, 2019		RX	Yes	Yes			Y	Y

Expired US Patents for ZYKADIA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novartis	ZYKADIA	ceritinib	CAPSULE;ORAL	205755-001	Apr 29, 2014
Novartis	ZYKADIA	ceritinib	CAPSULE;ORAL	205755-001	Apr 29, 2014
Novartis	ZYKADIA	ceritinib	TABLET;ORAL	211225-001	Mar 18, 2019
Novartis	ZYKADIA	ceritinib	CAPSULE;ORAL	205755-001	Apr 29, 2014
Novartis	ZYKADIA	ceritinib	CAPSULE;ORAL	205755-001	Apr 29, 2014
Novartis	ZYKADIA	ceritinib	TABLET;ORAL	211225-001	Mar 18, 2019

EU/EMA Drug Approvals for ZYKADIA

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Novartis Europharm Limited	Zykadia	ceritinib	EMEA/H/C/003819Zykadia is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK) positive advanced non small cell lung cancer (NSCLC) previously treated with crizotinib.	Authorised	no	no	no	2015-05-06

International Patents for ZYKADIA

When does loss-of-exclusivity occur for ZYKADIA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Costa Rica

Croatia

Cuba

Cyprus

Denmark

Dominican Republic

Ecuador

El Salvador

Eurasian Patent Organization

European Patent Office

France

Georgia, Republic of

Guatemala

Honduras

Hong Kong

Hungary

Israel

Japan

Jordan

Lithuania

Luxembourg

Malaysia

Mexico

Montenegro

Morocco

Netherlands

New Zealand

Norway

Peru

Poland

Portugal

San Marino

Serbia

Slovenia

South Africa

South Korea

Spain

Taiwan

Tunisia

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering ZYKADIA around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	361916
Australia	3395301
Australia	765151
Brazil	0108841
Brazil	PI0108841	derivado de pirimidina, processo para prepapar o mesmo, e composição farmacêutica
Canada	2399196	COMPOSES DE PYRIMIDINE (PYRIMIDINE COMPOUNDS)

Supplementary Protection Certificates for ZYKADIA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2091918	CA 2015 00047	Denmark		PRODUCT NAME: CERITINIB ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/15/999 (C(2015)3218) 20150506
2091918	C20150037 00157	Estonia		PRODUCT NAME: TSERITINIIB;REG NO/DATE: EU/1/15/999 08.05.2015
2091918	92785	Luxembourg		PRODUCT NAME: CERITINIB OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI. FIRST REGISTRATION: 20150508
2091918	PA2015034	Lithuania		PRODUCT NAME: CERITINIBUM; REGISTRATION NO/DATE: EU/1/15/999 20150506
1272477	92824	Luxembourg		PRODUCT NAME: CERITINIB OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI. FIRST REGISTRATION: 20150508
1272477	CA 2015 00050	Denmark		PRODUCT NAME: CERITINIB ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/15/999 20150508

ZYKADIA (Zykadia®; ceritinib) market dynamics and financial trajectory: exclusivity, competitive threats, and revenue outlook

Last updated: June 23, 2026

ZYKADIA (ceritinib) has moved from oncology launch growth into mature, shrinking sales as newer ALK inhibitors captured the sequential-treatment pathway. Financial trajectory is defined by the end of exclusivity and the replacement effect from next-generation ALK agents with improved tolerability and dosing convenience.

What drives ZYKADIA (ceritinib) market dynamics in ALK-positive NSCLC treatment?

Zykadia is an ALK tyrosine kinase inhibitor (TKI) used in ALK-positive metastatic non-small cell lung cancer (NSCLC). Market dynamics depend on (1) line-of-therapy positioning, (2) adverse event profile and dose management burden, (3) access and payer preferences within ALK sequencing, and (4) competing mechanisms such as next-generation ALK TKIs and combination strategies.

How does ZYKADIA fit in ALK TKI sequencing and treatment guidelines?

The practical market reality in ALK-positive metastatic NSCLC is that oncologists frequently select among multiple ALK TKIs based on efficacy-to-toxicity tradeoffs, CNS penetration, dosing schedules, and prior exposure. Next-generation ALK inhibitors have steadily shifted first-line preference in many geographies, compressing addressable share for earlier agents.

What clinical differentiators influence uptake for ceritinib?

Uptake has been shaped by:

• Tolerability and gastrointestinal toxicity management
• Dosing frequency and food requirements that increase real-world administration complexity (compared with later agents)
• CNS activity expectations as clinical practice evolved toward agents with stronger intracranial response profiles

How has ZYKADIA’s revenue trajectory changed since launch?

ZYKADIA’s revenue profile follows the standard pattern for an oncology TKI that faced rapid competitive replacement after newer ALK TKIs entered:

• Launch phase: initial share capture as the earlier ALK option
• Expansion and peak: sales scale as physicians establish ALK testing and incorporate TKIs
• Maturity: plateau as competitive entrants take share in first-line and preferred sequencing
• Decline: sustained erosion as newer ALK agents become dominant and as indication scopes mature

What financial line items typically govern ZYKADIA’s trajectory?

Revenue trajectory is driven by:

• Net sales from remaining label usage across geographies
• Share loss to next-generation ALK TKIs
• Reduced incremental prescriptions as patients move earlier to preferred agents
• Limited upside from new lines of therapy once sequencing solidifies

When does ZYKADIA lose exclusivity and what is the generic or biosimilar risk profile?

ZYKADIA is a small-molecule drug; there is no biosimilar pathway. The exclusivity and generic risk profile is therefore tied to patent expiration and any remaining formulation or method-of-use protections listed in the US Orange Book.

What exclusivity timelines apply to ceritinib in the US?

The exclusivity and patent-driven timeline is determined by:

• Composition-of-matter patents covering ceritinib
• Any method-of-use patents tied to specific ALK-positive NSCLC settings
• Formulation or dosing-regimen patents (if any are Orange Book-listed)

What are the generic entry dynamics for ceritinib?

Generic entry for ceritinib would hinge on:

• ANDA feasibility once relevant patents expire
• Potential Paragraph IV filings if unexpired patents exist for listed claims
• First generic incentives given the remaining prescriber adoption and payer coverage realities

What patents protect ceritinib and how strong is the patent estate for ZYKADIA?

A full, accurate patent estate map requires Orange Book listings and US and international patent families with grant and expiration dates. Without those specific listings and family data, a complete and accurate “how many patents” view cannot be produced.

What is the Orange Book status of ZYKADIA (ceritinib) and which claims are typically challenged via Paragraph IV?

A precise Orange Book status requires the current listing set: patent numbers, expiration dates, and claim types for ZYKADIA. Without those listings, it is not possible to provide a complete and accurate status summary or identify which claim sets are most likely to be targeted.

What patent litigation affects ZYKADIA (ceritinib) and what outcomes matter for generic launch timing?

A litigation-impact assessment depends on:

• Filed Paragraph IV actions
• Court dockets and claim construction outcomes
• Settlement agreements and their terms (trigger dates, caps, carve-outs)

Without case identifiers and dockets tied to ZYKADIA, a complete litigation map cannot be generated.

How do settlements and launch carve-outs typically change the ZYKADIA competitive clock?

For small-molecule oncology TKIs, settlements usually determine:

• Launch date windows for first ANDA filers
• Carve-outs for specific label indications, strengths, or dosing forms
• Whether subsequent filers accelerate entry after first entry

Without settlement terms tied to ZYKADIA, no accurate launch-timing conclusions can be made.

How do ZYKADIA and competing ALK inhibitors compare on market share and revenue impact?

From a market-structure perspective, ZYKADIA competes in the ALK-positive metastatic NSCLC setting with newer ALK TKIs that gained preference as treatment paradigms shifted. The key comparison axes that translate into revenue impact are:

• Line-of-therapy adoption: first-line share is typically hardest hit
• Dosing convenience: schedules that simplify adherence improve retention
• Tolerability and discontinuation rates: better-managed toxicities reduce treatment gaps
• CNS efficacy: intracranial response can drive physician preference

Which competitor classes most compress ZYKADIA sales?

• Next-generation ALK TKIs that moved into preferred first-line or faster sequencing positions
• CNS-focused ALK agents in settings where intracranial response drives selection
• Combination strategies and broader targeted options that reduce sequential use of older ALK agents

What formulation and dosing patents can limit generic substitution for ZYKADIA?

Generic substitution in oncology small molecules is constrained by:

• Formulation patents tied to release characteristics and stability
• Patents covering specific dosing regimens (dose, frequency, fed/fasted conditions)
• Manufacturing process patents if they are claim-protected and listed

A complete formulation and dosing patent inventory requires Orange Book and patent family claim mapping tied to ZYKADIA.

How do payer dynamics and access restrictions affect ZYKADIA net sales?

Oncology payer behavior in ALK-positive NSCLC tends to:

• Favor preferred brands within prior authorization and step therapy frameworks
• Restrict non-preferred use unless specific criteria are met (prior exposure, intolerability)
• Convert to alternative ALK agents when they become formulary-preferred

ZYKADIA’s mature sales profile typically reflects tightened payer access as competitors became preferred.

What regulatory and labeling changes affect ZYKADIA uptake over time?

Regulatory-driven market dynamics include:

• Label expansions or narrowing
• Treatment line reclassification as new evidence emerges
• Safety communications that affect dose management and persistence

A labeling timeline requires FDA label revisions and supplement dates for ceritinib, which are not available in the provided inputs.

Commercial outlook: what is the revenue sensitivity for ZYKADIA versus ALK competitor cycles?

Revenue sensitivity is highest when:

• Preferred first-line ALK therapies expand coverage
• New evidence supports earlier use of next-generation agents
• Patent-driven generic pressure increases brand substitution

For ZYKADIA specifically, the direction of travel remains downwards under typical ALK class competition once newer agents consolidate sequencing.

Key Takeaways

• ZYKADIA’s market dynamics are dominated by ALK TKI sequencing pressure from newer agents with improved practical use.
• The financial trajectory has transitioned from early share capture to maturity and replacement-driven decline.
• Generic and Paragraph IV risk depends on Orange Book-listed patent expirations and any active litigation; those specifics are required for a complete and accurate timeline.
• Payer access and tolerability-driven persistence typically govern incremental demand more than new marketing.

FAQs

1. What drives real-world discontinuation of ceritinib versus next-generation ALK inhibitors?
2. How do prior authorization policies for ALK-positive NSCLC shift ZYKADIA prescriptions?
3. What type of US patent claims (composition, method-of-use, formulation) most often block ceritinib ANDAs?
4. How does CNS response influence physician selection among ALK TKIs after ZYKADIA?
5. What indicators best predict remaining market size for mature oncology TKIs like ZYKADIA?

References (APA)

1. FDA. (n.d.). Drug approval and label information for ceritinib (ZYKADIA). US Food and Drug Administration.
2. FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. US Food and Drug Administration.
3. FDA. (n.d.). Safety communications and prescribing information updates for ceritinib. US Food and Drug Administration.